Skip to content

US · NPCE · MEDICAL - DEVICES

NeuroPace, Inc. (NPCE) intrinsic value and stock valuation

$7.95as of 2026-11-21 · Mkt cap 467.08M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NeuroPace, Inc. DCF and intrinsic value

InvestorsCraft values NPCE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NPCE’s statements →

NeuroPace, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Mountain View, CA 94043 neuropace.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$100M+19.4% 5y CAGRd
20192025
Net income
-$-21.46M
20192025
Free cash flow
-$-11.34M
20192025
Total equity
$19M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$100M$79.9M$65.4M$45.5M$45.2M
Operating income-$-16.34M-$-21.67M-$-27.17M-$-40.79M-$-23.74M
Net income-$-21.46M-$-27.14M-$-32.96M-$-47.08M-$-36.08M
EPSd-$-655.87K-$-931.69K-$-1.28M-$-1.91M-$-2.17M
Operating cash flow-$-11.01M-$-17.95M-$-19.7M-$-36.87M-$-24.58M
Capital expenditure-$-330K-$-310K-$-170K-$-600K-$-380K
Free cash flow-$-11.34M-$-18.25M-$-19.87M-$-37.47M-$-24.96M
Total assets$105.6M$94.7M$107.7M$114.1M$133.6M
Total debt$70.8M$73.3M$72.4M$69.8M$49.9M
Net debt$49.2M$59.9M$54.3M$63.2M$30.7M
Total equity$19M$8.01M$20.7M$34.8M$73.5M
Cash and short-term investments$61.1M$52.8M$66.5M$77.4M$115.6M
Income statement
20252024202320222021
Revenue$100M$79.9M$65.4M$45.5M$45.2M
Cost of revenue$22.8M$20.8M$17.3M$13M$11.8M
Gross profit$77.2M$59.1M$48.1M$32.5M$33.4M
Research and development expenses$27.9M$23.7M$20.8M$22M$18.2M
Selling, general and administrative expenses$65.7M$57.1M$54.5M$51.3M$39M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$93.6M$80.8M$75.3M$73.3M$57.2M
Cost and expenses$116.3M$101.6M$92.6M$86.3M$68.9M
Interest income$2.82M$3.02M$3.05M$1.58M$450K
Interest expense$7.46M$8.8M$8.52M$7.53M$7.41M
Depreciation and amortization$1.95M$1.77M$1.6M$2.99M$300K
Ebitda-$-12.06M-$-16.57M-$-22.83M-$-36.57M-$-28.37M
Operating income-$-16.34M-$-21.67M-$-27.17M-$-40.79M-$-23.74M
Total other income/expenses, net-$-5.13M-$-5.47M-$-5.78M-$-6.29M-$-12.34M
Income before tax-$-21.46M-$-27.14M-$-32.96M-$-47.08M-$-36.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-21.46M-$-27.14M-$-32.96M-$-47.08M-$-36.08M
Weighted average shares outstanding$32.7M$29.1M$25.9M$24.6M$16.6M
Weighted average diluted shares outstanding$32.7M$29.1M$25.9M$24.6M$16.6M
Balance sheet
20252024202320222021
Cash and short-term investments$61.1M$52.8M$66.5M$77.4M$115.6M
Net receivables$14.7M$12.9M$12.3M$7.48M$7.09M
Inventory$16.9M$13.4M$11.2M$9.71M$7.82M
Total current assets$94.1M$81.3M$92.7M$97.7M$132.8M
Property, plant and equipment, net$11.3M$12.9M$14.4M$15.9M$600K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$11.5M$13.3M$14.9M$16.4M$750K
Total assets$105.6M$94.7M$107.7M$114.1M$133.6M
Accounts payable$2.22M$2.95M$2.33M$2.15M$1.38M
Short-term debt$2.12M$1.86M$1.63M$1.42M$0.00
Deferred revenue$140K$560K$1.09M$0.00$0.00
Total current liabilities$17.8M$15.2M$16.2M$11M$9.3M
Long-term debt$68.7M$71.5M$70.8M$68.4M$49.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$68.7M$71.5M$70.8M$68.4M$50.8M
Capital lease obligations$9.84M$13.8M$15.4M$16.9M$0.00
Total liabilities$86.5M$86.6M$87M$79.3M$60.1M
Common stock$30K$30K$30K$30K$20K
Retained earnings-$-552.41M-$-530.95M-$-503.81M-$-470.85M-$-423.77M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-1.11M-$-270K
Total equity$19M$8.01M$20.7M$34.8M$73.5M
Total investments$39.4M$39.3M$48.4M$70.8M$96.4M
Total debt$70.8M$73.3M$72.4M$69.8M$49.9M
Net debt$49.2M$59.9M$54.3M$63.2M$30.7M
Cash flow statement
20252024202320222021
Net income-$-21.46M-$-27.14M-$-32.96M-$-47.08M-$-36.08M
Depreciation and amortization$1.95M$1.77M$1.6M$2.99M$300K
Stock-based compensation$11.1M$10.3M$9.56M$8.35M$4.29M
Change in working capital-$-4.01M-$-5.45M-$-2.48M-$-4.79M$370K
Accounts receivable-$-1.83M-$-540K-$-4.85M-$-390K$1.3M
Inventory-$-3.67M$250K-$-1.7M-$-2.13M-$-1.16M
Accounts payable-$-730K$670K$240K$650K$480K
Net cash provided by operating activities-$-11.01M-$-17.95M-$-19.7M-$-36.87M-$-24.58M
Investments in property, plant and equipment-$-330K-$-310K-$-170K-$-600K-$-380K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-330K$8.99M$23M$23.8M-$-85.4M
Common stock issued$71.8M$3.28M$7.89M$0.00$109.1M
Common stock repurchased-$-49.55M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19.6M$4.33M$8.13M$490K$102.5M
Net change in cash$8.26M-$-4.63M$11.5M-$-12.58M-$-7.45M
Cash at end of period$21.8M$13.6M$18.2M$6.73M$19.3M
Operating cash flow-$-11.01M-$-17.95M-$-19.7M-$-36.87M-$-24.58M
Capital expenditure-$-330K-$-310K-$-170K-$-600K-$-380K
Free cash flow-$-11.34M-$-18.25M-$-19.87M-$-37.47M-$-24.96M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NeuroPace, Inc.

        NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

        CEO
        Joel D. Becker
        Employees
        209
        Beta
        1.89

        Explore

        Frequently asked questions

        What is the intrinsic value of NeuroPace, Inc. (NPCE)?

        NeuroPace, Inc. (NPCE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NPCE undervalued?

        NPCE trades at a price of $7.95 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.